Integrated BioPharma (INBP) Stock Price, News & Analysis

Company Overview

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States and Luxembourg. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized health-care providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

Key Stats

• Today's Range: $0.29 to $0.29
• 50-Day Range: $0.26 to $0.39
• 52-Week Range: $0.16 to $0.42
• Volume: 2,500 shs
• Average Volume: 19,429 shs
• Market Capitalization: $8.79 million
• P/E Ratio: 9.67
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Integrated BioPharma Stock Analysis - MarketRank™

Integrated BioPharma scored higher than 21% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Integrated BioPharma.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Integrated BioPharma is 9.67, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.59.

Price to Earnings Ratio vs. Sector

The P/E ratio of Integrated BioPharma is 9.67, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.62.

Price to Book Value per Share Ratio

Integrated BioPharma has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.05% of the float of Integrated BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Integrated BioPharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Integrated BioPharma has recently increased by 1,500.00%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Integrated BioPharma does not currently pay a dividend.

Dividend Growth

Integrated BioPharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.05% of the float of Integrated BioPharma has been sold short.

Short Interest Ratio / Days to Cover

Integrated BioPharma has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Integrated BioPharma has recently increased by 1,500.00%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

News Sentiment

Integrated BioPharma has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Integrated BioPharma this week, compared to 0 articles on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Integrated BioPharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

67.20% of the stock of Integrated BioPharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 25.25% of the stock of Integrated BioPharma is held by institutions.

INBP Stock Analysis - Frequently Asked Questions

How have INBP shares performed this year?

Integrated BioPharma's stock was trading at $0.3297 at the beginning of 2025. Since then, INBP stock has decreased by 12.0% and is now trading at $0.29.
View the best growth stocks for 2025 here.

How do I buy shares of Integrated BioPharma?

Shares of INBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Integrated BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Integrated BioPharma investors own include GSK (GSK), Invitae (NVTA), Exxon Mobil (XOM), Autodesk (ADSK), Adaptive Biotechnologies (ADPT), Analog Devices (ADI) and Adaptimmune Therapeutics (ADAP).

Company Calendar

• Today: 4/02/2025
• Next Earnings (Estimated): 5/08/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:INBP
• CIK: 1016504
• Web: www.integratedbiopharma.com
• Phone: (973) 926-0816
• Fax: 973-926-1735
• Employees: 150
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.03
• Trailing P/E Ratio: 9.67
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $110,000.00
• Net Margins: 1.78%
• Pretax Margin: 2.79%
• Return on Equity: 4.79%
• Return on Assets: 3.54%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.26
• Quick Ratio: 1.27

Sales & Book Value

• Annual Sales: $50.32 million
• Price / Sales: 0.17
• Cash Flow: $0.04 per share
• Price / Cash Flow: 7.35
• Book Value: $0.65 per share
• Price / Book: 0.45

Miscellaneous

• Outstanding Shares: 30,301,000
• Free Float: 9,939,000
• Market Cap: $8.79 million
• Optionable: Not Optionable
• Beta: 0.89